Formulation Development
Bluejay Therapeutics Announces First Patient Dosed in AZURE-1 Global Pivotal Clinical Trial Evaluating Brelovitug as a Monotherapy Treatment for Chronic Hepatitis D
Bluejay Therapeutics recently announced the first patient has been dosed in its AZURE-1 global pivotal clinical trial evaluating brelovitug (also known as BJT-778) for the…
Silo Pharma Achieves Key Milestone With First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment
Silo Pharma, Inc. recently announced first dosing in an investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset,…
Nanoscope Announces Publication of Clinical Data on Vision Restoration in Retinitis Pigmentosa
Researchers with Nanoscope Therapeutics Inc. recently announced the publication of a paper, A synthetic opsin restores vision in patients with severe retinal degeneration, in Molecular…
Porosome Therapeutics Unveils Groundbreaking Discovery in Alzheimer’s Disease Research & Treatment
Porosome Therapeutics, Inc. recently announced its latest development in identifying the secretory dysfunction responsible for Alzheimer’s Disease along with advancements in therapeutic neuronal nanomachines. These innovations…
First Patient Dosed in Immutep’s TACTI-004 Phase 3 Trial in First Line Non-Small Cell Lung Cancer
Immutep Limited recently announced the first patient has been successfully dosed in the Company’s pivotal TACTI-004 Phase 3 trial. TACTI-004 will evaluate Immutep’s eftilagimod alfa,…
Tiziana Life Sciences Announces Yale University Commences Intranasal Foralumab Dosing in Phase 2 Multiple Sclerosis Trial
Tiziana Life Sciences, Ltd. recently announced dosing of new patients at Yale MS Center, which is participating in our multicenter Phase 2 clinical trial evaluating…
Character Biosciences Raises $93 Million to Advance Precision Medicine for Progressive Eye Diseases
Character Biosciences recently announced an oversubscribed $93 million Series B financing round to accelerate the advancement of its pipeline of precision therapies to treat degenerative…
IMUNON Finalizes Phase 3 Study Design With FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
IMUNON, Inc. recently announced the US FDA is aligned with the protocol for the Phase 3 pivotal trial, called OVATION 3, of its lead candidate…
Journey Medical Corporation Launches Emrosi (40-mg Minocycline Hydrochloride Modified-Release Capsules, 10-mg Immediate Release & 30- mg Extended Release) for the Treatment of Rosacea
Journey Medical Corporation recently announced the launch of and the first prescriptions filled for Emrosi (40-mg Minocycline Hydrochloride Modified-Release Capsules, 10-mg immediate release and 30-mg…
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function & Survival in MYBPC3 Cardiomyopathy Models
Tenaya Therapeutics, Inc. recently announced the publications of positive preclinical data for TN-201, the company’s gene therapy candidate for Myosin-Binding Protein C3 (MYBPC3)-associated hypertrophic cardiomyopathy…
Upperton Pharma Solutions Wins Champion Award at 2025 CDMO Leadership Awards in Small Molecule Dosage Form Category
Upperton Pharma Solutions is proud to announce its selection as Champion Winner in the Small Molecule Dosage Form – International category at the 2025 CDMO…
Traws Pharma’s Bird Flu Drug Candidate Presented at ICAR
Traws Pharma, Inc. recently announced that positive data supporting the potential for tivoxavir marboxil (TXM) as a bird flu treatment was presented yesterday in a…
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204
Silexion Therapeutics Corp. recently announced it has completed an expanded development plan for its next-generation siRNA candidate, SIL204, which the company’s management will be presenting…
Wugen Announces Dosing of First Patients in Pivotal Trial of Off-the-Shelf, Allogeneic, CD7-Targeted CAR-T Cell Therapy WU-CART-007
Wugen, Inc. recently announced the dosing of the first patients in its pivotal Phase 2 study evaluating WU-CART-007, a potential first-in-class, investigational, anti-CD7 CAR-T cell…
Esperion Aligns With FDA to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous & Homozygous Familial Hypercholesterolemia
Esperion recently announced that following meetings with the US FDA, it has gained alignment on a regulatory path forward for initiating Phase 3 studies of…
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
Indaptus Therapeutics, Inc. recently provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20. As…
Candel Therapeutics & IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
Candel Therapeutics, Inc. together with IDEA Pharma, a Division of SAI MedPartners (IDEA) recently announced a strategic commercial partnership. Under this agreement, IDEA will provide…
Second Data Safety Monitoring Board Issues Positive Recommendation to Continue BriaCell’s Phase 3 Study in Metastatic Breast Cancer
BriaCell Therapeutics Corp. recently announced the external Data Safety Monitoring Board (DSMB), an independent group of experts who review and monitor the safety data of…
Dyadic Announces Funding Award to Use C1 to Accelerate Development of Protein-Based Vaccines
Dyadic International, Inc. recently announced it has received a funding award from CEPI to use C1 to accelerate the development of protein-based vaccines. CEPI is…
Longeveron Announces Positive Type B Meeting With FDA Regarding Pathway to BLA for Laromestrocel in Alzheimer’s Disease
Longeveron Inc. recently announced the positive outcome of a Type B meeting with the US FDA, supporting the advancement of laromestrocel (Lomecel-B), a proprietary, scalable,…
